Aeglea Biotherapeutics

28 articles with Aeglea Biotherapeutics

• 

  New CEOs Named in BioSpace’s Biopharma Movers and Shakers for July 23

  7/23/2018

  It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.

• Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion

  5/30/2018

  Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.

• 

  Aeglea BioTherapeutics Updates Phase I/II Trial Data

  3/13/2018

  Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

• Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase I/II Trial with Pegzilarginase (AEB1102)

  11/29/2017

  Clinical agreement reached with FDA to enable pediatric dosing.

• Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

  11/8/2017

  On September 30, 2017, Aeglea had available cash, cash equivalents and marketable securities of $55.7 million.

• Aeglea BioTherapeutics Inks Clinical Collaboration with Merck

  10/16/2017

  Aeglea and Merck will evaluate the combination of Aeglea's AEB1102 with Merck’s anti-PD-1 therapy, KEYTRUDA for the treatment of patients with small cell lung cancer.

• Aeglea Doses Two Patients In Repeat Dose Part Of Phase I/II Clinical Trial For The Treatment Of Arginase 1 Deficiency

  9/6/2017

• Aeglea Appoints James Wooldridge, M.D. As Chief Medical Officer

  7/11/2017

• Aeglea Prices Public Offering Of Common Stock

  6/6/2017

• Aeglea Announces Proposed Public Offering Of Common Stock

  6/6/2017

• Aeglea Provides AEB1102 Program And Corporate Update

  5/23/2017

• Aeglea Provides Corporate Update And Reports First Quarter 2017 Financial Results

  5/9/2017

• Everything's Bigger in Texas: Aeglea Quickly Growing into Leading Austin Biotech

  9/14/2016

• Aeglea Announces Closing Of Initial Public Offering And Partial Exercise Of The Underwriters’ Option

  4/13/2016

• Aeglea Appoints Dr. Anthony Quinn To Board Of Directors

  3/15/2016

• Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Hematological Malignancies

  3/15/2016

• 

  Top 20 Life Science Startups to Watch in the U.S.

  1/26/2016

  BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.

• Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Arginase I Deficiency

  1/7/2016

• What You Need to Know About Aeglea

  12/2/2015

• Aeglea Doses First Patient In Phase I Study Of AEB1102 For Treatment Of Solid Tumors

  10/26/2015